Compare iShares MSCI Singapore ETF (EWS) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs TransMedics Group Inc — how do they compare? iShares MSCI Singapore ETF trades at $31.81, while TransMedics Group Inc trades at $76.31 (market cap $2.61B). The key difference: iShares MSCI Singapore ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| EWS | TMDX | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $32.09 | $150.42 |
52-Week Low | $26.47 | $61.99 |
Market Cap | — | $2.61B |
Enterprise Value | — | $3.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS trades at $31.825, up 0.62% with strong technical momentum as moving averages signal bullish alignment. The ETF benefits from Singapore's economic resilience and AI-driven growth narrative, though key financial ratios remain undisclosed. Recent news highlights Singapore's strategic positioning in Asian markets and financial sector strength, with a dividend of $0.52 scheduled for June 2026.
Outlook remains positive given technical strength and regional economic tailwinds, but overbought RSI readings suggest near-term consolidation risk. The concentrated financials exposure (54% of holdings) ties performance to banking sector stability, while AI infrastructure investments offer growth catalysts. Investors should monitor Singapore's economic policies and global market volatility.
TransMedics (TMDX) trades at $76.89, up 3.08% today, with a bullish technical signal from moving averages. The company reported strong profitability with a 27.04% net income margin and 45.22% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in PAD Aviation aims to expand its organ transplant logistics network in Europe, enhancing its competitive position.
The outlook remains positive with a consensus price target of $108.71, representing 41% upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion investments and competitive threats. Investors should weigh strong long-term growth initiatives against near-term execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
